Background. Inadequate food intake plays an important role in the development of malnutrition in continuous ambulatory peritoneal dialysis (CAPD) patients.
Introduction
Malnutrition is a major complication of continuous ambulatory peritoneal dialysis (CAPD) and is associated with increased morbidity and mortality [1] . Insulin-like growth factor-I (IGF-I) is produced in tissues throughout the body under the influence of growth hormone (GH). In addition, nutrition is one of the main regulators of circulating IGF-I [2, 3] . Circulating IGF-I has been proposed as a valid sensitive marker of (mal−) nutrition in subjects on CAPD, which may have advantages above serum albumin and other markers of nutritional state [4] [5] [6] [7] . On the other hand, reduced bioavailability of IGF-I may play a role in decreasing muscle protein synthesis [8] .
The GH-IGF-I axis shows major changes in chronic renal failure (CRF). Despite elevated GH levels, IGF-I secretory rate by the liver is reduced in CRF, possibly as a result of hepatic GH resistance [9] . There is also a resistance to IGF-I action, which may be the result of circulating inhibitors [8] . The amount of these circulating inhibitors increases in patients with CRF along with the decrease in glomerular filtration rate [10] .
Circulating IGF-I bioactivity measured by 'classic' bioassays has been reported to be low in CRF [11] . Since these 'classic' bioassays suffered from high variability as well as long assay duration, IGF-I bioactivity is at present almost exclusively estimated by immunological determinations of total IGF-I. In contrast, circulating total IGF-I levels measured by immunoassays have been reported as normal or elevated in CRF. However, the results of IGF-I immunoassays may not necessarily correspond to the fraction of IGF-I being accessible to the IGF-I receptor [12] .
Recently, a rapid and accurate IGF-I bioassay was developed as alternative to the 'classic' bioassays, named the kinase receptor activation assay (IGF-I KIRA) [12, 13] . The IGF-I KIRA quantifies phosphorylation of tyrosine residues of the activated IGF-I receptor (IGF-IR) as a measure of IGF-I bioactivity in serum. In contrast to commonly used IGF-I immunoassays, the IGF-I KIRA is sensitive for modifications of IGF-IR activation by circulating insulin-like growth factor binding proteins (IGFBPs) and IGFBP proteases [12, 14] .
We hypothesized that measuring circulating IGF-I bioactivity by the IGF-I KIRA method could help to enhance our insights in the alterations of the IGF-I system in CAPD patients. Considering that a substantial portion of patients undergoing CAPD have insufficient protein and calorie intake due to anorexia, we previously evaluated in CAPD patients the metabolic effects of dialysate containing amino acids with glucose (AA plus G) and observed that this solution improved protein metabolism both in fasting [15] and in fed [16] patients on peritoneal dialysis. From the same study, we here evaluate whether circulating IGF-I bioactivity is a more sensitive index to monitor acute responses to nutritional interventions than total IGF-I. In addition, in these CAPD patients we compared basal IGF-I bioactivity and total IGF-I in relation to nutritional status.
Materials and methods

Study population
Twelve patients on CAPD were recruited from the Peritoneal Dialysis Unit of the Erasmus Medical Centre (Erasmus MC). Inclusion criteria were: stable patients who were on peritoneal dialysis for more than 3 months and a weekly total Kt/V > 1.7 (total Kt/V = urea clearance per week (Kt) divided by urea distribution volume (V), as delivered by peritoneal dialysis plus residual renal function). Exclusion criteria were peritonitis, other infections or inflammatory diseases in the previous 6 weeks, malignancy and life expectancy <6 months. The Medical Ethics Committee of the Erasmus MC approved the study, and informed consent was obtained from all patients.
Study design
The study design has been published in detail [16] . Briefly, an openlabel, randomized, crossover study of 2 days with a 1-week interval was performed.
On the two study days, all patients came at 8.00 a.m. into the hospital and stayed at the Department of Nephrology of the Erasmus MC. Dialysis was performed during daytime for 9 h, while the patients consumed a liquid diet comparable in nitrogen and energy content to their habitual diet ( Figure 1 ). The total food volume was divided into 11 equal portions ( Figure 1 ). The first two meal portions were given at half-hourly intervals, and the remaining nine portions were given at hourly intervals thereafter ( Figure 1 ).
For dialysis, either dialysate that contained a mixture of amino acids and glucose (AA plus G) (Nutrineal 1.1% plus Physioneal 1.36% to 3.86%; Baxter BV, Utrecht, the Netherlands) or dialysate that contained glucose only (G) was used. The AA plus G dialysate was obtained by mixing one bag of 2.5 L of Nutrineal 1.1% (containing 27.5 g of AA) and four bags of 2.5 L of Physioneal 1.36% to 3.86% G (see [16] for more details). The night before the study days, all patients underwent dialysis with Extraneal. Because metabolic steady-state conditions are not achieved with a standard CAPD scheme, six daytime dialysate exchanges on the two study days were performed using an automatic cycler (HomeChoice, Baxter B.V.).
Blood measurements
At 8.20 a.m., two catheters were inserted into superficial veins of both arms. Baseline blood samples were collected before starting the oral feeding. Blood samples for IGF-I parameters were taken before the first dialysate exchange (fasting state) and at the end of the study (Figure 1 ). Circulating IGF-I bioactivity was measured using an in-house IGF-I kinase receptor activation assay as previously described [17] . This latter assay is based on another principle than IGF-I immunoassays [13, 17] . Briefly, IGF-I binding to the IGF-I receptor (IGF-IR) results in autophosphorylation of tyrosine residues located within the intracellular kinase domain, being the first step in the intracellular signal cascade. The IGF-I KIRA uses human embryonic renal cells stably transfected with cDNA of the human IGF-IR gene (293 EBNA IGF-IR) and quantifies phosphorylation of tyrosine residues of the IGF-IR to assess IGF-I bioactivity. Serum total IGF-I was measured by a solid-phase, enzyme-labelled chemiluminescent immunometric assay (CLIA) Immulite 2000 IGF-I supplied by Siemens Medical Solutions Diagnostics, Los Angeles, USA.
Both IGF-I bioactivity and total IGF-I levels were compared with the age-specific normative range values for IGF-I. Reference values for IGF-I bioactivity and total IGF-I have been published in previous reports [17, 18] . Both for IGF-I bioactivity and total IGF-I individual Z-scores were calculated using the following formula: Z-score = (x − average x/ SD) where x is the actual IGF-I bioactivity or IGF-I level, average x is the mean IGF-I bioactivity or IGF-I level at that age, and SD is standard deviation for the mean at that age.
Insulin was measured by a chemiluminescent immunometric assay (Immulite 2000 Insulin; Siemens Medical Solutions Diagnostics, Los Angeles, USA). Amino acids were measured by ion-exchange chromatography on a Biochrome 20 amino acid dialyser with ninhydrin detection (Biochrome, Cambridge, UK). Serum glucose, creatinine, albumin, prealbumin and transferrin were performed by standard laboratory methods. Residual renal function was derived as the mean of renal urea and creatinine clearance (millilitres per minute) and derived from PD adequest 2.0 software Baxter.
Other measurements
Body mass index (BMI) was defined as weight divided by the square of height (kilograms per square metre). Subjective global assessment (SGA) as described by Detsky et al. is based on clinical parameters [19] . Patients were classified according to their nutritional status into three categories: A, good nutritional status; B, moderate malnutrition; C, severe malnutrition. The normalized protein equivalent of nitrogen appearance (nPNA) was evaluated by the urea kinetic model (PD Adequest 2.0 software, Baxter) [16] .
Effects on protein metabolism were studied using whole-body protein turnover (WBPT). Previously, we performed an open-label randomized crossover study on 2 days with 6 days interval comparing the effect of AA plus G dialysate with dialysate containing only G [16] . For the present study, we used data on WBPT, which were all derived from our previously performed study [16] .
Statistical analysis
Data are expressed as medians with ranges unless otherwise indicated.
All variables were tested using the Shapiro-Wilk test for normality. When no normality of distribution was found, data were log-transformed. One-way ANOVA was used to test differences between subjects with different SGA classifications. The Wilcoxon signed rank test was used to compare outcomes in IGF-I parameters and other variables between before and after dialysis. The paired t-test was used to compare differences between the two treatment regimens (AA plus G versus G dialysis). Pearson's correlation coefficients were calculated to assess the associations between variables. Pearson's correlation coefficients for IGF-I were calculated after adjustment for age. A P value of 0.05 or less was considered statistically significant. Data were analysed using SPSS 15 for Windows (SPSS Inc., Chicago, IL).
Results
In Table 1 , the baseline characteristics of the study population are presented.
According to the SGA classification, four out of 12 patients were moderately malnourished. The mean BMI of these latter four patients tended to be lower, and the time on peritoneal dialysis was longer than that of patients with a good nutritional status, but these differences were not statistically significant (Table 1) . At baseline albumin, pre- Bioactive IGF-I in acute responses to nutrition in CAPD patients 941 albumin and transferring levels did not differ between subjects with different SGA classifications.
In subjects with a good nutritional status (SGA A), Zscores for circulating total IGF-I were in the upper half of the normal range (Table 2; Figure 2 ). Z-scores for total IGF-I exceeded the normal range (i.e. Z-score > 2.0 SD) in patients with moderate malnutrition (SGA B) ( Table 2 ). The differences in total IGF-I between both groups were not statistically significant (Table 2; Figure 2 ).
Mean circulating IGF-I bioactivity did not differ between patients with SGA A and SGA B (Table 2; Figure 2 ). Z-scores for IGF-I bioactivity were in the lower half of the normal range (Table 2; Figure 2 ). Three subjects (two classified as SGA B) had IGF-I bioactivity outside and below the normal range (i.e. Z-score < 2.0 SD) ( Table 2) . IGF-I bioactivity was not significantly related to total IGF-I (r = 0.50, P = 0.10).
Both IGF-I bioactivity and total IGF-I levels did not significantly decrease with age (IGF-I bioactivity: r = −0.16, P = 0.63; total IGF-I levels: r = 0.30, P = 0.34).
Total IGF-I levels and IGF-I bioactivity were inversely related to creatinine clearance, although these latter relationships missed statistical significance (r = −0.58, P = 0.06 and r = −0.48, P = 0.11, respectively).
In the fed state both after AA plus G and after G dialysis, IGF-I bioactivity increased compared to baseline (Table 3; Figure 3) . However, the increase in IGF-I bioactivity was only significant after AA plus G dialysis (P = 0.02). Compared to baseline, no changes in circulating total IGF-I levels were observed in both treatment arms (Table 3 ; Figure 3 ).
In the basal state, serum bicarbonate, creatinine, urea, glucose and insulin levels did not statistically differ between both treatment arms (data not shown). After dialysis, insulin and glucose levels increased significantly com- pared with baseline in both treatment arms (Table 4) . After AA plus G dialysis, plasma essential and non-essential amino acid levels significantly increased compared to G dialysis (data not shown). Protein loss and excretion of urea in dialysate did not differ with either type of dialysate (data not shown). Results of whole-body protein turnover after AA plus G dialysate and after G dialysate from this study have previously been published [16] . After AA plus G dialysate leucine flux, leucine oxidation, protein intake and protein synthesis significantly increased compared with G dialysate (P = 0.001, P < 0.001, P < 0.001 and P = 0.039, respectively). There were no significant differences in protein breakdown after AA plus G dialysate and G dialysate, respectively (P = 0.346). In addition, overall net protein balance was not significantly different between both treatment arms (P = 0.347). Both after AA plus G and after G dialysis, IGF-I bioactivity was significantly related to leucine flux, leucine oxidation and protein intake but not to protein synthesis, protein breakdown and overall net protein balance (Table  5) . Moreover, IGF-I bioactivity was not related to insulin levels at the end of dialysis (AA plus G: r = 0.24, P = 0.47; G: r = 0.38, P = 0.25).
There were no significant relationships between total IGF-I levels and WBPT parameters after AA plus G dialysis (Table 5) . After G dialysis, total IGF-I levels were significantly related to protein breakdown but not other components of WBPT (Table 5) .
Neither basal IGF-I bioactivity nor total IGF-I levels were related to nPNA (IGF-I bioactivity: r = 0.37, P = 0.27; total IGF-I: r = 0.52, P = 0.09).
Discussion
The major finding of the present study in CAPD patients is that in the fed state, both after AA plus G and after G dialysis, circulating IGF-I bioactivity increased. This increase in IGF-I bioactivity occurred while no changes in circulating total IGF-I levels were observed. Our observa- Changes at the end of dialysis compared to baseline (=100%). *P = 0.02; paired t-test. Fig. 3 . Top: Changes in circulating total IGF-I levels in the fed state after G and after AA and G dialysate, respectively (basal state = 100%). Bottom: Changes in circulating IGF-I bioactivity in the fed state compared to baseline after G and after AA and G dialysate, respectively (basal state = 100%). AA plus G dialysate = combined amino acids plus glucose dialysis, G dialysate = glucose dialysis. *P < 0.05 versus baseline.
Bioactive IGF-I in acute responses to nutrition in CAPD patientstion suggests that IGF-I bioactivity rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients. Only after AA plus G dialysate, the rise in IGF-I bioactivity was significant. The lack of a significant rise in IGF-I bioactivity after G dialysis may be due to the small number of patients. Alternatively, it cannot be ruled out that the larger amount of AA accounts for a significant rise of IGF-I bioactivity.
Previously it was suggested that nutrients influence synthesis and action of IGF-I and its binding proteins (IGFBPs) at multiple levels [3] . Both protein and energy are needed for IGF-I gene expression [2, 20] . Although protein is a very strong factor in changing hepatic IGF-I gene expression, a period of 9 h is likely too short to induce measurable changes in circulating IGF-I levels [20] . Therefore, the rise in IGF-I bioactivity at the end of the dialysis period probably reflects diet-induced changes in circulating IGFBP levels as nutrition is also a major regulator of the circulating IGFBP levels [2] . Dietary manipulations may change the circulating levels of IGFBPs more rapidly and thereby IGF-I bioactivity [2] . Although it has been found that circulating IGFBP-3 concentrations are relatively constant throughout the day, IGFBP-1 is markedly and rapidly suppressed by nutrient intake, and this effect is mediated primarily by increased insulin, glucose and probably amino acid concentrations [21] [22] [23] [24] [25] . Insulin may also selectively stimulate the transport of IGFBP-1 to the extravascular space [26] . Both mechanisms might be involved in the changes of IGF-I bioactivity. However, the design of our study was not sufficient to disentangle which components of nutritional interventions were affecting the increase of IGF-I bioactivity.
A weakness of our study could be that we did not measure the six IGFBP levels. Because IGFBPs control IGF-I bioavailability, they are believed to exert both stimulatory and inhibitory effects on IGF-I actions [27] . In addition, IGF-I bioactivity may be further controlled by posttranslational modifications of IGFBPs (e.g. partial proteolytic degradation by specific IGFBP proteases and selective dephosphorylation) [27] . Thus, the interpretation of the overall effects of these six IGFBPs on IGF-I activity is very difficult, especially in CRF which is characterized by substantial changes in the circulating IGF system. In this respect, the IGF-I KIRA assay may have an important advantage over measuring IGFBPs: it gives an overall and integrated picture by capturing the complex interactions between IGF-I, IGFBPs, proteases and the IGF-I receptor since the IGF-I KIRA directly measures IGF-I receptor activation in vitro. Thus, the IGF-I KIRA probably provides a more accurate measure of IGF-I action in vivo than any other currently available model based on immunoassays of IGFBP blood levels, since it incorporates complex interactions with binding proteins and proteases.
We observed no change in total IGF-I levels during dialysate administration in both treatment arms. In accordance with our findings, Pupim et al. also reported no changes in total IGF-I levels during intradialytic parenteral nutrition to chronic haemodialysis patients despite a significant positive effect on protein and energy metabolism [28] .
Although there was a marked rise of plasma insulin levels in both treatment arms after dialysate administration, the absence of a relationship between insulin and IGF-I bioactivity does not support an insulin-mediated increase in IGF-I bioactivity.
Our results provide evidence that in CAPD patients acute changes in circulating IGF-I bioactivity are associated with nutrient intake and that in this respect IGF-I bioactivity is a more sensitive index for monitoring acute responses to nutritional interventions than total IGF-I.
In both treatment arms, IGF-I bioactivity was positively related to leucine flux, leucine intake and leucine oxidation. The competing processes of amino acid deposition (synthesis for maintenance) and loss (oxidation) play an important role in maintaining protein metabolism [29] . If protein intake is not adequate, the amino acid supply is limited, and oxidation is reduced to a greater extent than is synthesis [30, 31] . Conversely, when amino acids are provided in excess, as probably was the case in our study, oxidation rather than synthesis is increased [30] . In other words, in this situation, leucine oxidation is a more sensitive index of adequacy of amino acid intake than is protein synthesis, changing in proportion to protein intake [31] . Thus, the positive relationships between IGF-I bioactivity, leucine flux, leucine intake and leucine oxidation in our study is consistent with our finding that circulating IGF-I bioactivity can be changed by amino acid intake: thus, our study provides evidence that an increase in circulating IGF-I bioactivity is likely the consequence of an increased amino acid and/or protein intake. In favour of this, it has been found that changes in nitrogen balance parallel changes in IGF-I [32] . By use of a 'classic' IGF-I bioassay, it has been reported that circulating IGF-I bioactivity is low in subjects on haemodialysis (HD) [11] . Our study confirms this finding for peritoneal dialysis (PD). Using a 'classic' porcine cartilage bioassay, Phillips et al. showed that circulating IGF-I bioactivity was reduced, and they hypothesized that IGF-I bioactivity was depressed because of the accumula- tion of dialysable inhibitors [11] . Some years later, these dialysable inhibitors were identified as IGFBPs, and it was demonstrated that IGF-I activity in blood samples of CRF patients was indeed restored after removal of IGFBPs by IGF-II chromatography [33] . Thus, the low IGF-I bioactivity in CAPD patients in our study may directly reflect sequestering of IGF-I by IGFBPs in the circulation. Most CAPD patients in our study showed total IGF-I serum levels in the normal range. This observation is in line with previous studies in patients undergoing maintenance HD [10, [33] [34] [35] . However, circulating total IGF-I levels exceeded even the normal range in some patients. This latter phenomenon was especially observed in patients with moderate malnutrition (SGA B). Although we did not measure IGFBP levels, previous studies have shown that serum of individuals with CRF contains increased levels of IGFBP-1, IGFBP-2, fragments of IGFBP-3, IGFBP-4 and IGFBP-6 [10, 34, 36] . It has been hypothesized that these IGFBPs accumulate largely because of reduced clearance: elevation of their serum levels is inversely related to glomerular filtration rate [10] . When IGFBPs are present in serum in large excess and a total IGF-I immunoassay is utilized that is subject to even a modest amount of binding protein interference, the measured total IGF-I levels may be artificially high [37] . This problem may be exacerbated in patients with underlying conditions that lower circulating IGF-I levels (like subjects with chronic renal failure and moderate malnutrition), since the decrease in IGF-I as well as the increase in IGFBPs results in more unsaturated IGFBPs and intensify the interference [37] . This may explain why in our study circulating total IGF-I levels exceeded the normal range especially in CAPD patients with moderate malnutrition.
Finally, several findings in our study appeared not to be statistically significant (e.g. comparison of IGF-I parameters between groups of SGA A vs. B and the correlation between insulin and IGF-I bioactivity). However, this may also have been due to the small number of patients included in our study.
In conclusion, the observed acute increase in IGF-I bioactivity in the fed state may be related to nutrition-induced changes in circulating IGFBPs. The present study suggests that IGF-I bioactivity rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients.
